🔍

Windlas Biotech Limited (WINDLAS)

₹917.40 -0.66% last close, 16 Oct

📊 NSE: WINDLAS 🏢 Pharmaceuticals - Indian - Formulations 📢 Latest filing: 12 Oct 2026 📝 Analysis written: 14 Dec 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Windlas Biotech's revenue was ₹248 Cr (+18.1% year on year, +4.2% on the previous quarter), and net profit ₹17.7 Cr (-0.1% year on year); the operating margin was 10.8%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹248	+18.1%	+4.2%
Operating profit	₹26.7	+0.6%	+6.7%
Net profit	₹17.7	-0.1%	+10.3%
EPS (₹)	8.46	+0.4%	+11.6%
Operating margin	10.8%	—	—

Full quarterly financials → Results calendar →

WINDLAS delivery percentage

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 53.08% of the WINDLAS shares traded on NSE were taken to delivery, against the stock's own 20-session average of 48.06%. That is close to its usual level.

53.08%Delivery, 16 Oct

48.06%Own 20-session average

0.9×Volume vs its average

₹917.40NSE close · -0.66%

Delivery in the last 5 sessions: 54.3% · 35.5% · 45.1% · 51.1% · 53.1%

Delivery across the market →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

Windlas Biotech: Chairman Vivek Dhariwal Resigns; Two Independent Directors Appointed for 5 Years

🟡 NEUTRAL ⭐ 5/10

MANAGEMENT 📅 12 Oct 2026, 06:49 PM

Windlas Biotech announced that Independent Director and Chairman of the Board, Mr. Vivek Dhariwal, has resigned effective October 12, 2026, citing personal reasons and prior commitments with no other material reasons stated. To reconstitute the board, the company appointed Mr. Aashish Mehra and Mr. Soni Saran Singh as Additional Independent Directors, both for a 5-year tenure subject to shareholder approval. Mr. Mehra brings over two decades of strategy experience in life sciences, while Mr. Singh brings over three decades of manufacturing leadership. The board overhaul comes as the company operates at a trailing-twelve-month revenue of Rs 942 Cr.

Resignation of Board Chairman and Independent Director Vivek Dhariwal effective October 12, 2026
Appointment of Mr. Aashish Mehra as Independent Director for a 5-year tenure effective October 12, 2026
Appointment of Mr. Soni Saran Singh as Independent Director for a 5-year tenure effective October 12, 2026
Both appointments are subject to the approval of shareholders

💡 Track the upcoming appointment of a new Board Chairman and monitor the voting outcome on the director appointments in the subsequent general meeting or postal ballot.

Windlas Biotech: Chairman Vivek Dhariwal Resigns; Two Independent Directors Appointed for 5 Years

🟡 NEUTRAL ⭐ 5/10

MANAGEMENT 📅 12 Oct 2026, 06:39 PM

Resignation of Board Chairman and Independent Director Vivek Dhariwal effective October 12, 2026
Appointment of Mr. Aashish Mehra as Independent Director for a 5-year tenure effective October 12, 2026
Appointment of Mr. Soni Saran Singh as Independent Director for a 5-year tenure effective October 12, 2026
Both appointments are subject to the approval of shareholders

💡 Track the upcoming appointment of a new Board Chairman and monitor the voting outcome on the director appointments in the subsequent general meeting or postal ballot.

Windlas Biotech Schedules Investor and Analyst Meetings for September 7, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 01 Sep 2026, 05:47 PM

Windlas Biotech Limited has informed the exchanges regarding its schedule of investor and analyst interactions on Monday, September 7, 2026. The company officials will hold virtual one-on-one sessions with ICICI Direct, Bajaj Broking, and Haitong Securities, along with a group investor session. Management clarified that only publicly available information will be discussed and no Unpublished Price Sensitive Information (UPSI) will be shared.

Four virtual investor interaction sessions scheduled for Monday, September 7, 2026
One-on-one sessions lined up with ICICI Direct (2:00 PM), Bajaj Broking (3:00 PM), and Haitong Securities (5:00 PM)
Group meeting scheduled with a pool of investors at 4:00 PM
Discussions strictly limited to publicly available information with no UPSI shared

💡 Track post-meet investor presentations or transcripts, if uploaded, to observe management commentary on injectable facility ramp-up and CDMO order volumes.

18% YoY Revenue Growth to Rs 248 Cr in Q1 FY27; Plant 6 Commercialization by H1

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 14 Aug 2026, 03:05 PM

Windlas Biotech reported its highest-ever quarterly revenue of Rs 248 crore in Q1 FY27, marking 14 consecutive quarters of growth. The CDMO segment was the primary driver, growing 29% YoY to Rs 207 crore, while the Trade Generics segment (Rs 30 crore) was impacted by the discontinuation of codeine-based products. Adjusted PAT (excluding Rs 7.2 crore non-cash ESOP expenses) grew 37% YoY to Rs 25 crore. The company is on track to commercialize Plant 6 by the end of H1 FY27, which is expected to add approximately Rs 3 crore in quarterly depreciation starting Q3.

Achieved highest-ever quarterly revenue of Rs 248 crore, an 18% YoY increase.
CDMO vertical grew 29% YoY to Rs 207 crore, now representing ~83% of total revenue.
Exports vertical recorded 79% YoY growth to Rs 11 crore, targeting semi-regulated markets.
Plant 6 commercialization scheduled for the end of H1 FY27 (September 2026).
Completed a Rs 47 crore buyback and declared a dividend of Rs 13 crore (Rs 6.30 per share).

💡 Watch for the successful commissioning of Plant 6 by September 2026 and its subsequent impact on margins as depreciation kicks in. Monitor the recovery in the Trade Generics segment as the company launches new products to replace the discontinued codeine portfolio.

Windlas Biotech Releases Q1 FY27 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 11 Aug 2026, 02:07 PM

Windlas Biotech has released the audio recording of its investor conference call for the quarter ended June 30, 2026. This follows the company's Q1 FY27 financial results and provides management's commentary on recent performance. The company currently operates with a TTM revenue of ₹904 Cr and an operating margin of 11.6%. Investors can access the recording via the company's website to review discussions on growth strategies, including the injectable facility ramp-up.

Audio recording of the Q1 FY27 conference call uploaded on August 11, 2026
Follows the initial call intimation provided to exchanges on August 5, 2026
Company maintains an annual installed capacity of 706.4 crore units across four facilities
TTM revenue stands at ₹904 Cr with a net profit of ₹66 Cr as of the latest reporting cycle

💡 Investors should review the upcoming written transcript for specific management commentary on the execution timeline of the new injectable facility and export growth in semi-regulated markets.

18% Revenue Growth to ₹248 Cr in Q1 FY27; CDMO Vertical Surges 29% YoY

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 10 Aug 2026, 04:08 PM

Windlas Biotech reported its 14th consecutive quarter of record revenue at ₹248 Cr for Q1 FY27, driven by a robust 29% growth in its core CDMO segment. Adjusted PAT (excluding non-cash ESOP expenses) grew 37% YoY to ₹25 Cr, though reported PAT stood at ₹18 Cr due to a ₹7.16 Cr ESOP charge. The company completed a ₹47 Cr share buyback and is on track to commercialize its new Plant-6 in H1 FY27. While the Trade Generics segment declined 32% due to product portfolio shifts, the Exports vertical showed strong momentum with 79% growth.

Revenue from operations reached a record ₹248 Cr, up 18% YoY from ₹210 Cr.
Generic Formulations CDMO vertical grew 29% YoY to ₹207 Cr, now contributing 84% of total revenue.
Adjusted EBITDA grew 26% YoY to ₹34 Cr with margins at 13.6%, excluding ₹7.16 Cr ESOP expenses.
Exports vertical grew 79% YoY to ₹11 Cr, reflecting successful penetration in semi-regulated markets.
Completed a ₹47 Cr share buyback without promoter participation and paid ₹13 Cr in dividends.

💡 Watch for the successful commercialization of Plant-6 in H1 FY27 and the ramp-up of the new injectables facility, which are key to sustaining the 18-20% growth guidance.

18% Revenue Growth in Q1 FY27; CDMO Vertical Up 29% YoY to Rs 207 Cr

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 10 Aug 2026, 04:05 PM

Windlas Biotech reported its 14th consecutive quarter of record revenue at Rs 248 Cr for Q1 FY27, an 18% YoY increase. While reported PAT remained flat at Rs 18 Cr due to a non-cash ESOP charge of Rs 7.16 Cr, adjusted PAT (excluding ESOP) grew 37% YoY to Rs 25 Cr. The core CDMO business showed strong momentum with 29% growth, offsetting a 32% decline in Trade Generics caused by the discontinuation of codeine-based products. The company maintains a strong liquidity position of Rs 251 Cr and is on track to commercialize Plant-6 in H1 FY27.

Achieved record quarterly revenue of Rs 248 Cr, marking 18% YoY growth and the 14th consecutive record quarter.
Generic Formulations CDMO vertical, the largest segment, grew 29% YoY to Rs 207 Cr.
Adjusted EBITDA (excluding Rs 7.16 Cr ESOP expense) grew 26% YoY to Rs 34 Cr with a 13.6% margin.
Exports vertical recorded 79% YoY growth to Rs 11 Cr, expanding penetration in semi-regulated markets.
Completed a Rs 47 Cr buyback (promoters did not participate) and declared a Rs 13 Cr dividend for FY26.

💡 Watch for the successful commercialization of Plant-6 in H1 FY27, which is expected to drive the next leg of growth through injectables. Additionally, monitor the recovery in the Trade Generics vertical as the company replaces discontinued codeine-based products with new launches.

Windlas Biotech Q1 Revenue Grows 18% YoY to ₹248 Cr; PAT Stagnant at ₹17.7 Cr

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 10 Aug 2026, 03:37 PM

Windlas Biotech reported a strong 18.1% YoY revenue growth for Q1 FY27, reaching ₹248.1 cr, up from ₹210.1 cr in the previous year. However, Net Profit (PAT) remained flat at ₹17.65 cr compared to ₹17.67 cr in Q1 FY26, as margins were pressured by a 34.4% increase in raw material costs. The company completed a ₹47 cr buyback of 4.7 lakh shares at ₹1,000 per share during the period, representing approximately 8.1% of its net worth. Following the dissolution of its US subsidiary, the company has transitioned to standalone-only financial reporting.

Revenue from operations increased 18.1% YoY to ₹248.1 cr from ₹210.1 cr.
Net Profit (PAT) remained flat at ₹17.65 cr, impacted by higher material costs of ₹168.7 cr vs ₹125.5 cr YoY.
Completed buyback of 470,000 equity shares at ₹1,000 per share, totaling ₹47 cr.
Employee benefit expenses rose 37.8% YoY to ₹44.4 cr, including ₹7.16 cr in share-based payment expenses.
Paid a dividend of ₹6.30 per share on July 31, 2026, totaling ₹13.0 cr.

💡 Investors should monitor the ramp-up of the new injectables facility and export growth to see if they can offset the current margin pressure from rising raw material and employee costs. The impact of the reduced share capital on EPS should be observed in the coming quarters.

August 11: Windlas Biotech schedules Q1 FY27 earnings call to discuss performance

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 05 Aug 2026, 03:06 PM

Windlas Biotech has announced its Q1 FY27 earnings conference call for August 11, 2026, at 11:30 AM IST. The management will discuss the financial results for the quarter ended June 30, 2026. This follows a fiscal year (FY26) where the company reported revenue of ₹903.6 Cr and a PAT of ₹66.5 Cr. Key focus areas for the call will likely include the ramp-up of the new injectable facility and the performance of the Trade Generics segment, which has seen a 40% CAGR over the last three years.

Conference call scheduled for August 11, 2026, at 11:30 AM IST
Discussion pertains to the financial performance for the quarter ended June 30, 2026
Company reported TTM revenue of ₹904 Cr and TTM PAT of ₹66 Cr leading into this period

💡 Monitor the Q1 FY27 financial results release prior to the call to assess growth against the company's 18-20% target.

Windlas Biotech Schedules Q1 FY27 Earnings Conference Call for August 11, 2026

🟡 NEUTRAL ⭐ 2/10

EARNINGS 📅 05 Aug 2026, 01:54 PM

Windlas Biotech Limited has scheduled its conference call to discuss the financial performance for the quarter ended June 30, 2026 (Q1 FY27). The call is set for August 11, 2026, at 11:30 AM IST, featuring the Managing Director and CEO/CFO. This follows a fiscal year (FY26) where the company achieved a revenue of ₹903.59 crore and a PAT of ₹66.47 crore. Investors will likely seek updates on the 18-20% growth target and the ramp-up of the new injectables facility.

Conference call scheduled for August 11, 2026, at 11:30 AM IST to discuss Q1 FY27 results.
Management participants include Mr. Hitesh Windlass (MD) and Ms. Komal Gupta (CEO and CFO).
The company reported a TTM revenue of ₹904 crore and a TTM PAT of ₹66 crore leading into this quarter.
The call will address performance for the period ending June 30, 2026.
Primary dial-in numbers provided are +91 22 6280 1256 and +91 22 7115 8157.

💡 Investors should review the Q1 FY27 financial results once released and listen to the call for management commentary on the injectable facility's progress and trade generics growth.

Windlas Biotech Shareholders Approve Rs 6.30 Final Dividend at 25th AGM

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 24 Jul 2026, 05:05 PM

Shareholders of Windlas Biotech Limited have approved all resolutions at the 25th Annual General Meeting held on July 23, 2026. Key approvals include the adoption of FY26 financial statements and a final dividend of Rs 6.30 per equity share. The voting process saw a 71.39% participation rate, with 100% of votes cast in favor of the dividend and financial adoption. Additionally, Dr. Tarashree Singhal was appointed as an Independent Director.

Final dividend of Rs 6.30 per equity share approved for the financial year 2025-26
Total voting participation reached 71.39% with 14,732,527 votes polled out of 20,636,229 shares
100% of the votes cast by both Promoters and Public Institutions were in favor of all major resolutions
Appointment of Dr. Tarashree Singhal as an Independent Director approved via special resolution
A total of 45,932 shareholders were on record as of the cut-off date, July 16, 2026

💡 Investors should monitor the company's upcoming disclosures for the dividend payment date and continue to track the ramp-up of the new injectable facility mentioned in previous growth strategies.

Windlas Biotech Shareholders Approve ₹6.30 Final Dividend at 25th AGM

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 24 Jul 2026, 05:00 PM

Windlas Biotech Limited concluded its 25th Annual General Meeting on July 23, 2026, with shareholders approving all six proposed resolutions with nearly 100% majority. Key approvals include the declaration of a final dividend of ₹6.30 per equity share for FY26 and the appointment of Dr. Tarashree Singhal as an Independent Director. Total voting participation stood at 71.39% of the total shares held, with promoters contributing 1.3 crore votes. The company continues to focus on its injectable segment and trade generics portfolio for future growth.

Final dividend of ₹6.30 per equity share approved for the financial year 2025-26
Total of 1,47,32,527 votes polled, representing 71.39% of the total 2,06,36,229 shares
All resolutions passed with 100% of votes in favor, including the re-appointment of Managing Director Mr. Hitesh Windlass
Notice of AGM was dispatched to 45,596 members as of the record date
Appointment of Dr. Tarashree Singhal as an Independent Director was ratified via special resolution

💡 Investors should monitor the dividend credit timeline and track the execution of the new injectable facility ramp-up, which is a key part of the company's 18-20% growth strategy.

₹6.30 Dividend Approved at Windlas Biotech 25th AGM; New Independent Director Appointed

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 23 Jul 2026, 03:07 PM

Windlas Biotech concluded its 25th Annual General Meeting on July 23, 2026, where shareholders approved a final dividend of ₹6.30 per equity share for FY25-26. This dividend represents a payout of approximately 20% relative to the TTM EPS of ₹31.61. The meeting also confirmed the re-appointment of Managing Director Mr. Hitesh Windlass and the appointment of Dr. Tarashree Singhal as an Independent Director. Operationally, the company remains focused on its injectable facility ramp-up and expanding its trade generics portfolio, which has historically grown at a 40% CAGR.

Approved a final dividend of ₹6.30 per equity share for the financial year 2025-26
Appointment of Dr. Tarashree Singhal as an Independent Director via Special Resolution
Re-appointment of Mr. Hitesh Windlass (Managing Director) and Mrs. Prachi Jain Windlass (Director)
63 members attended the meeting conducted via Video Conferencing
Adoption of Audited Standalone and Consolidated Financial Statements for the year ended March 31, 2026

💡 Investors should monitor the upcoming record date for the ₹6.30 dividend and track the execution of the new injectable facility ramp-up in subsequent quarterly results.

Regulation 74(5) Compliance: Windlas Biotech Submits Share Certificate for June 2026 Quarter

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 10 Jul 2026, 02:20 PM

Windlas Biotech has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by its Registrar and Share Transfer Agent, MUFG Intime India Private Limited, covers the quarter ended June 30, 2026. This is a standard procedural filing confirming that share certificates received for dematerialization have been processed and the records updated. It has no impact on the company's financial performance or business operations.

Compliance certificate submitted for the quarter ended June 30, 2026
Issued by Registrar and Share Transfer Agent MUFG Intime India Private Limited
Filed in accordance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
Document dated July 10, 2026, following the close of the first quarter of FY27

💡 No action is required as this is a routine administrative filing. Investors should focus on upcoming quarterly results to track the company's 18-20% growth guidance and the ramp-up of its new injectable facility.

Windlas Biotech Schedules Group Investor Meeting for July 14, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Jul 2026, 07:32 PM

Windlas Biotech has scheduled a virtual group meeting with analysts and institutional investors for July 14, 2026, at 3:00 PM. The company will discuss publicly available information, focusing on its business operations which generated TTM revenue of ₹904 Cr. This interaction comes as the company maintains a steady growth trajectory, with its most recent quarterly PAT (March 2026) standing at ₹16 Cr and an operating profit margin of 11.6%.

Virtual group meeting scheduled for July 14, 2026, starting at 3:00 PM
Company reported TTM revenue of ₹904 Cr and TTM PAT of ₹66 Cr
Promoter holding stands at 63.31% as of May 2026, up from 61.9% in March 2026
Current annual installed operating capacity is 706.4 crore units across four facilities

💡 Investors should watch for any post-meeting transcripts or presentations that may provide updates on the ramp-up of the new injectables facility and the expansion of the Trade Generics portfolio.

View All WINDLAS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

In H1 FY26, the Generic Formulation CDMO vertical grew 18% YoY, Trade Generics & Institutional grew 25% YoY, and the Exports vertical grew 23% YoY. For Q2 FY26, these segments grew 18%, 24%, and 13% YoY respectively, contributing to a total revenue of INR 222 Cr.

Geographic Revenue Split

The company is expanding its footprint in semi-regulated geographies through its Exports vertical, which grew 23% in H1 FY26. Domestic operations comprise the majority of revenue through CDMO and Trade Generics (INR 172 Cr in FY25).

Profitability Margins

Gross margin expanded by 70 bps YoY in H1 FY26 and 68 bps YoY in Q2 FY26. Historical PAT margins were 8.0% in FY25, 9.2% in FY24, and 8.3% in FY23. The company achieved a 30% ROCE and 27% ROE for H1 FY26.

EBITDA Margin

EBITDA margin (excluding ESOPs) stood at 12.7% in FY25 (INR 97 Cr) and H1 FY26 EBITDA reached INR 55 Cr, representing a 25% YoY growth. The margin has improved from 10.3% in FY20 to a steady 12.7% in recent years.

Capital Expenditure

The company utilized INR 50 Cr from IPO proceeds to fund capex for the new injectables facility. Total net cash used in investing activities was INR 74 Cr in FY25 and INR 92 Cr in FY24.

Credit Rating & Borrowing

ICRA reaffirmed an [ICRA]A+ (Stable) rating for long-term fund-based facilities (INR 58.70 Cr) and [ICRA]A1 for short-term unallocated facilities. Interest coverage was healthy at 43.5 times in FY21, and the company remains net debt-free with INR 237 Cr liquidity.

⚙️ Operational Drivers

Raw Materials

Raw materials and packaging materials are the primary inputs, representing approximately 62.1% of revenue (COGS of INR 472 Cr on INR 760 Cr revenue in FY25). Specific chemical names are not disclosed.

Capacity Expansion

Current annual installed operating capacity is 706.4 crore units across four manufacturing facilities in Dehradun. Expansion is focused on the new injectables segment to support profitability and scale ramp-up.

Raw Material Costs

COGS was INR 472 Cr in FY25 (62.1% of revenue), up from INR 396 Cr in FY24. Procurement strategies involve long-term relationships to manage pricing and supply terms for raw materials and packaging.

Manufacturing Efficiency

The company achieved an asset turnover of 3.8x in FY25. Efficiency is driven by a focus on high-volume complex generics and chronic/sub-chronic dosage forms (59% of portfolio).

Logistics & Distribution

Trade Generics are sold directly to stockists and distributors without medical representative support to maintain a low-cost distribution model.

📈 Strategic Growth

Expected Growth Rate

18-20%

Growth Strategy

Growth will be achieved through the ramp-up of the new injectable facility, expanding the Trade Generics brand portfolio (which grew from 128 brands in FY20 to 400 in FY25), and increasing export penetration in semi-regulated markets. The company targets high-margin complex generics (67% of portfolio) and chronic therapies.

Products & Services

Pharmaceutical formulations (tablets, capsules, liquids), injectables, and trade generic medicines across chronic and sub-chronic therapeutic areas.

Brand Portfolio

The company owns 400 brands in its Trade Generics segment and has IP rights for formulation technology across 99% of products sold, including 4,340 brands in Complex Generics.

New Products/Services

Foraying into the injectables segment and expanding the Trade Generics portfolio, which has seen a 40% CAGR in revenue over the last three years.

Market Expansion

Targeting high-growth semi-regulated geographies in the Exports vertical, which grew 23% in H1 FY26.

Market Share & Ranking

Windlas is one of the leading formulations CDMO players in the organized domestic market, though it remains a moderate-sized player overall with FY25 revenue of INR 760 Cr.

Strategic Alliances

Maintains long-standing customer relationships with leading pharmaceutical companies for CDMO services; specific partner names for JVs are not disclosed.

🌍 External Factors

Industry Trends

Large pharma companies are shifting capex toward high-end products like biosimilars and regulated markets, creating an ecosystem where they outsource standard formulations to established CDMOs like Windlas.

Competitive Landscape

Competes with other domestic CDMOs and generic manufacturers; market dynamics are shifting toward specialized CDMOs as large players outsource non-core manufacturing.

Competitive Moat

Moat is built on 25 years of expertise, IP rights on 99% of products, and high entry barriers in complex generics (67% of portfolio). Sustainability is supported by long-term CDMO contracts and brand ownership in Trade Generics.

Macro Economic Sensitivity

Sensitive to the growth of the Indian Pharmaceutical Market (IPM), which grew 7.7% in Q2 FY26. Volume sensitivity is high as the industry saw a 0.2% volume decline in the same period.

Consumer Behavior

Increasing demand for affordable high-quality generic drugs is driving the 40% CAGR in the Trade Generics vertical.

Geopolitical Risks

Exposure to semi-regulated markets in the Exports vertical (23% growth) introduces risks related to trade barriers and local regulatory changes in those regions.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by the Companies Act 2013 (Section 143) and WHO-GMP standards for pharmaceutical manufacturing. Compliance with quality standards is central to the CDMO strategy.

Environmental Compliance

Operates three WHO-GMP compliant plants, ensuring adherence to international manufacturing standards.

Taxation Policy Impact

Effective tax rate is approximately 23.7% based on FY25 PBT of INR 80 Cr and Tax of INR 19 Cr. The company previously received an INR 8 Cr tax benefit from the WHC merger.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the successful ramp-up and capacity utilization of the new injectable facility, which carries higher depreciation costs (INR 28 Cr in FY25 vs INR 13 Cr in FY24).